You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

69 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI), 
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Oct 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
May 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
May 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Apr 2024
Regimen
Cancer Type:
Breast, 
Genitourinary, 
Renal cell / Kidney, 
Lung, 
Non-Small Cell, 
Small Cell, 
Unknown Primary
Intent: Palliative
Aug 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Aug 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
Sep 2022
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Mar 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Adjuvant, Curative, Palliative
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Exceptional Access Program
    pomalidomide - In combination with isatuximab and dexamethasone for relapsed or refractory multiple myeloma, according to specific criteria
Feb 2024

Pages